# HPAP-066- Donor Summary

| | | | |
|---|---|---|---|
| ***HPAP*** | *-066* | ***UNOS*** | |
| **Recovery OPO** | GLDP | **Allocation Via** | UPENN ☐ nPOD ☒ |
| **Age (years)** | 58 | **DCD** | YES ☐ NO ☒ |
| **Race** | African American | **DBD** | YES ☒ NO ☐ |
| **Sex** | M ☐ F☒ | **Admission to Cross Clamp** | 51 Hours 24 Mins. |
| **ABO (Rh)** | O+ | **Cross Clamp Time** | 7/30/2020 23:05 |
| **BMI (Kg/m$^2$)**<br>**Weight (kg)**<br>**Height (cm)** | 31.07<br>92.7<br>172.72 | **Cold Ischemia Time*** | 11 Hours 24 Mins. |
| **Cause of Death** | CVA/Stroke | **Preservation Solution** | UW ☒ HTK☐ |
| **Mechanism of Injury** | Intracranial Hemorrhage/Stroke | **Organs Recovered** | Heart ☐ Kidney ☒<br>Lung ☒ Pancreas ☒<br>Liver ☒ Intestine ☐ |
| **Cardiac Arrest/Downtime** | Yes ☒<br>No ☐ | **Intraoperative time lapse from liver to pancreas removal from the peritoneal cavity:** | 00 Hours 32 Mins. |
| **CPR / Time** | Yes ☒<br>No ☐<br>5 minutes | **Organs Discarded** | Heart ☐ Kidney ☐<br>Lung ☐ Pancreas ☐<br>Liver ☐ Intestine ☐ |
| **Total Est. Downtime** | 5 Minutes | **Blood Culture** | No Growth |
| **Date /Time of Admission** | 7/28/2020 19:30 EST | **PHS High Risk** | YES ☐ NO ☒ |
| | | **Acute Lung Injury** | Bibasilar atelectasis |
| | | | |

***Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.**

# HPAP-066- Donor Summary

## Medical History:

| | | Duration | Medications | Compliance |
|---|---|---|---|---|
| **Type of Diabetes** | None | ---- | ---- | ---- |
| **History of cancer** | ---- | ---- | ---- | ---- |
| **CAD** | ---- | ---- | ---- | ---- |
| **Hypertension** | Yes | 30-35 Years | Labetolol 30 years<br>clonidine 25 years<br>amlodipine 30 years | Yes |
| **Hyperlipidemia** | ---- | ---- | ---- | ---- |
| **Autoimmune disease** | ---- | ---- | ---- | ---- |
| **Family History** | CAD ☒ | Diabetes ☐ | Auto immune disease ☐ | Others: |
| **Surgical History:** | ---- | | | |
| **Comments:** | Father died of MI | | | |

## Hemodynamic Profile

| | | |
|---|---|---|
| **Average BP During Hospitalization (mmHg)** | 122/72 | |
| **Average Low BP During Hospitalization** | 92/46 | **Duration: 15 Minutes** |
| **Average BP in OR (mmHg)** | 128/70 | |
| **Average Low BP in OR (mmHg)** | 89/58 | **Duration: 1 Minute** |
| **Average HR in OR (bpm)** | 78 | |
| **ABG-pH range** | 7.28 – 7.55 | |

## INTERVENTION

## Blood Products/Meds Transfused Before Organ Recovery

| Product | Amount (ml) | Units | Total (ml) |
|---|---|---|---|
| **Fresh Frozen Plasma** | ---- | ---- | ---- |
| **PRBCs** | ---- | ---- | ---- |
| **Platelets** | ---- | ---- | ---- |
| **Norepinephrine (Levophed)** | ---- | ---- | ---- |
| **Vasopressin** | ---- | I unit/hr during Echocardiogram, 3:32 hrs before organ recovery | |
| **Neo-Synephrine** | ---- | ---- | ---- |
| **Epinephrine** | ---- | ---- | ---- |
| **Phenylephrine** | ---- | 125 mcg/min started 28:03 hrs before organ recovery | |
| **Dopamine** | ---- | ---- | ---- |

# HPAP-066- Donor Summary

## Blood Products/Meds Transfused Intraoperative

| Product | Amount (ml) | Units | Total (ml) |
|---|---|---|---|
| **Fresh Frozen Plasma** | ---- | ---- | ---- |
| **PRBCs** | ---- | ---- | ---- |
| **Platelets** | ---- | ---- | ---- |
| **Norepinephrine (Levophed)** | ---- | ---- | ---- |
| **Vasopressin** | ---- | ---- | ---- |
| **Neo-Synephrine (phenylephrine)** | ---- | 75/mcg/min | ---- |
| **Epinephrine** | ---- | ---- | ---- |
| **Dopamine** | ---- | ---- | ---- |
| **Heparin** | ---- | 30,000 | ---- |

## Initial Autoantibody Screening (nPOD): ELISA

**Not performed for HPAP-T2D program**

| GAD-65 | IA-2 |
|---|---|
| Not Done | Not Done |

## Confirmatory results: Radioimmuno Assay (RIA)

| | GAD-65 (unit/ml) | IA-2 (unit/ml) | Insulin AAB (unit/ml) | ZnT8 (unit/ml) |
|---|---|---|---|---|
| **Results** | 0 | 0 | 0.001 | -0.003 |
| **Cut-off values** | 20 | 5 | 0.01 | 0.02 |

*Sample obtained at time of organ recovery.

| | C-peptide (ng/ml) | Proinsulin |
|---|---|---|
| Results | 3.88 | Not Done |

*Sample obtained at time of organ recovery.

## HLA (OPO)*

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **Class 1** | **A** | 30 | 36 | **Class II** | **DR** | 17 | 15 |
| | **B** | 35 | 58 | | **DR51** | 51 | N-Negative |
| | **C** | 04 | 07 | | **DR52** | 52 | N-Negative |
| | **Bw4** | Positive | | | **DR53** | N-Negative | N-Negative |
| | **Bw6** | Positive | | | **DQB1** | 2 | 6 |
| | [redacted] | | | | **DQA1** | 01 | 05 |
| | | | | | **DPB1** | 11:01 | 17:01 |
| | | | | | | | |
| **Comment:** | | | | | | | |

# HPAP-066- Donor Summary

## Confirmatory HLA (UPENN)* Not performed for HPAP-T2D program

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **Class 1** | **A** | | | **Class II** | **DRB1** | | |
| | **B** | | | | **DRB3** | | |
| | **C** | | | | **DRB4** | | |
| | | | | | **DRB5** | | |
| | | | | | **DQB1** | | |
| | | | | | **DQA1** | | |
| | | | | | **DPB1** | | |
| | | | | | **DPA1** | | |

*HLA typing performed using NGS

## Infectious Disease Serology

| | | Hemo/Plasma Dilution Status | |
|---|---|---|---|
| **Test** | **Result** | **Qualified** | **Non-Qualified** |
| **EBV IgG** | Positive | ✓ | - |
| **EBV IgM** | Negative | ✓ | - |
| **CMV** | Negative | ✓ | - |
| **HBcAb** | Non-Reactive | ✓ | - |
| **HBsAg** | Non-Reactive | ✓ | - |
| **HCV Ab** | Non-Reactive | ✓ | - |
| **HIV I/II** | Non-Reactive | ✓ | - |
| **Syphilis** | Non-Reactive | ✓ | - |
| **Procleix Ultrio** | - | - | - |
| **Ultrio HBV** | Non-Reactive | ✓ | - |
| **Ultrio HCV** | Non-Reactive | ✓ | - |
| **Ultrio HIV** | Non-Reactive | ✓ | - |
| **Toxoplasma Ab** | Negative | ✓ | - |
| **SARS-COV-02** | Not detected | ✓ | - |

# HPAP-066- Donor Summary

## Laboratory Panel

| | Initial | Peak | Terminal |
|---|---|---|---|
| **Na (mEq/L) (135-145)** | 140 | 154 | 152 |
| **Creatinine (<1.5)** | 1.29 | 1.29 | 0.97 |
| **Glucose (mg/dL) (60-150)** | 131 | 212 | 144 |
| **HbA1C%** | **6.2** | - | - |
| **Total bilirubin (0-1.0)** | 0.5 | 0.5 | 0.3 |
| **SGOT (AST) (0-40)** | 74 | 74 | 33 |
| **SGPT (ALT) (5-35)** | 106 | 108 | 69 |
| **Alkaline phosphatase (45-110)** | 62 | 65 | 52 |
| **Serum Amylase (23-851)** | 128 | 128 | 35 |
| **Serum Lipase (0-80)** | 119 | 119 | 12 |
| **WBC (THO/uL) (4.5-11.0)** | 8.7 | 18.4 | 18.4 |
| **Hgb (g/dL) (12-16)** | 13.5 | 14.2 | 10.1 |
| **Platelets (THO/uL) (150-350)** | 330 | 330 | 251 |
| **INR (<2.0)** | 1.2 | 1.3 | 1.3 |

## Urinalysis

| | 1st | 2nd | 3rd | 4th |
|---|---|---|---|---|
| **Glucose** | Negative | Negative | - | - |

## Medications During Hospitalization

| | | | |
|---|---|---|---|
| **Steroids**** | ---- | | |
| **Diuretics** | ---- | | |
| **T3 Protocol** | ---- | | |
| **T4 Protocol*** | Yes 40 mcg/hr | | |
| **Insulin**** | | | |
| **Antihypertensive** | Clevidipine 7.5 mg/hr for the duration of 5:31 hrs , 42:37 hrs before organ recovery | | |
| **Vasodilators** | ---- | | |
| **DDAVP**** | ---- | | |
| **Total parenteral nutrition** | ---- | | |
| **Other** | ---- | Specify | |

*T4 protocol: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

*Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015:7 17-27.*

** Excluding T4 Protocol